405 filings
10-Q
2024 Q1
KA
Kineta Inc
Quarterly report
15 May 24
4:05pm
8-K
KA
Kineta Inc
15 May 24
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
4:03pm
ARS
2023 FY
KA
Kineta Inc
26 Apr 24
Annual report to shareholders
4:06pm
DEFA14A
KA
Kineta Inc
26 Apr 24
Additional proxy soliciting materials
4:03pm
DEF 14A
KA
Kineta Inc
Definitive proxy
26 Apr 24
4:00pm
8-K
p9prprvc
24 Apr 24
Entry into a Material Definitive Agreement
4:00pm
8-K
c7dshh wj2yyc
18 Apr 24
Departure of Directors or Certain Officers
4:00pm
8-K
a5s32 bul7n0mx
8 Apr 24
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
4:02pm
8-K
rrl9u 21x4dd
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
8-K
3oq48
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
cy8e w26asn591zp
29 Feb 24
Kineta Announces Restructuring and Exploration of Strategic Alternatives
7:00am
8-K
v3n3p9bazezb5
17 Jan 24
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
8:30am
8-K
xn81j2c 39
5 Jan 24
Regulation FD Disclosure
4:30pm
8-K
dk6 rmue19z20x8g
15 Dec 23
Entry into a Material Definitive Agreement
8:30am
EFFECT
3rwpl 266ukvmbizhll
15 Nov 23
Notice of effectiveness
12:15am
424B3
fs2v uh3g6w5q1
13 Nov 23
Prospectus supplement
5:28pm
CORRESP
3ambx3v15ea299m6z6r
9 Nov 23
Correspondence with SEC
12:00am
UPLOAD
3awny01xrn2
9 Nov 23
Letter from SEC
12:00am
8-K
z48r8tl0pl566zr8bn
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am